Newsletter Tool

To view this email as a web page, click here

Today's Rundown

Trial chief tips AstraZeneca COVID-19 vaccine for 2020 data drop
Healthcare is ramping up AI investments during COVID. But the industry is still on the fence about Google, Amazon. Here's why
Pfizer goes solo on US shot distribution, opting out of government channels
Singapore startup develops 60-second COVID-19 breathalyzer test
Fosun follows BioNTech in changing COVID-19 vaccine, plans bridging study for Chinese filing
HHS wants to review most of its existing regulations and sunset burdensome, obsolete rules
Healthcare roundup: Economy tops pandemic as key concern for voters, exit polls show
Biopharma roundup: AstraZeneca falls short of UK shot production timeline, official says; Russia's vaccination plan hits manufacturing snags: report
BD nets Dutch government contract for over 9M rapid antigen tests for COVID-19

Featured Story

Trial chief tips AstraZeneca COVID-19 vaccine for 2020 data drop

By Nick Paul Taylor

AstraZeneca has a good chance of delivering late-phase data on its COVID-19 vaccine this year, the chief investigator of the Oxford Vaccine Trial said. The timing gives AstraZeneca a “small chance” of being able to start distributing the AZD1222 vaccine in the U.K. before Christmas.

Healthcare is ramping up AI investments during COVID. But the industry is still on the fence about Google, Amazon. Here's why

By Heather Landi

Healthcare organizations are ramping up their investments in artificial intelligence in response to the COVID-19 pandemic, according to survey data. But they are not turning to tech giants like Google and Amazon to deploy these technologies. Here's why.

Pfizer goes solo on US shot distribution, opting out of government channels

By Arlene Weintraub

If Pfizer's COVID-19 mRNA vaccine is approved, it will not use the government’s chosen distribution provider, McKesson Corp., but rather its own just-in-time system to deliver it, a top executive said. The need to keep the vaccine at an ultra-cold temperature is one reason for that choice.

Singapore startup develops 60-second COVID-19 breathalyzer test

By Conor Hale

Singapore’s Breathonix has said a clinical trial of its COVID-19 breathalyzer test was able to achieve at least 90% accuracy after screening participants on-site for 60 seconds.

Fosun follows BioNTech in changing COVID-19 vaccine, plans bridging study for Chinese filing

By Nick Paul Taylor

Fosun Pharma has stopped development of BioNTech’s first COVID-19 vaccine, following the lead of its German partner by picking BNT162b2 as the candidate to take to market.

HHS wants to review most of its existing regulations and sunset burdensome, obsolete rules

By Robert King

HHS introduced a proposed rule intended to determine whether existing regulations are creating a burden or obsolete, with the review potentially affecting nearly 2,500 existing rules.

Healthcare roundup: Economy tops pandemic as key concern for voters, exit polls show

By Healthcare Staff

Follow along with the latest COVID-19 news straight from the Fierce Healthcare team.

Biopharma roundup: AstraZeneca falls short of UK shot production timeline, official says; Russia's vaccination plan hits manufacturing snags: report

By Eric Sagonowsky,Angus Liu,Kyle Blankenship,Conor Hale,Fraiser Kansteiner

AstraZeneca missed its target to supply 30 million U.K. shot doses by September, a British official said. Russia's vaccination plan reportedly hit manufacturing and quality control hurdles. Singapore's Breathonix is testing a COVID-19 breathalyzer. The FDA warned about possible false positives from antigen tests.

BD nets Dutch government contract for over 9M rapid antigen tests for COVID-19